Recent NRG Oncology studies reveal significant improvements in cancer treatment outcomes across multiple cancers. A Phase II trial combining proton therapy with immunotherapy showed promising survival in glioblastoma patients. Another trial indicated improved quality of life for localized intermediate-risk prostate cancer patients treated with stereotactic body radiation therapy compared to conventional regimens. Further, patient-reported outcomes in oropharyngeal cancer showed comparable results between intensity-modulated radiation therapy and proton therapy, supporting evolving radiation modalities in oncology.